Skip to main content
SpringerLink
Log in

Women’s Bone Health: Breathing Life into the Skeleton

  • Chapter
  • First Online:
Musculoskeletal Health in Women

  • 1068 Accesses

Abstract

The shape and size of bones define our physical selves and provide protection for internal organs and leverage sites for muscles. These mechanical properties of the skeleton create a static image of bone health, with impaired microarchitecture of bone and consequent fracture hallmarks of tissue failure. Yet bone is constantly created, modeled, and remodeled throughout the course of a woman’s life, and its structure and health are intimately involved with calcium metabolism and sustenance of bone marrow cells. This chapter will discuss the systemic and local factors that affect bone health throughout the life of a woman, emphasizing the vulnerable, living quality of bone that is often lost in translation when tests are interpreted and treatments recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rauch F. Fetal and neonatal bone development. In: Rosen CJ, editor. Primer in metabolic bone disease. Washington, D.C: American Society for Bone and Mineral Research; 2009. p. 72–4.

    Google Scholar 

  2. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-A review of recent evidence. Autoimmun Rev. 2013;12(10):976–89. doi:10.1016/j.autrev.2013.02.004. pii: S1568-9972(13)00040-2.

    Article  PubMed  CAS  Google Scholar 

  3. Hollis BW, Wagner CL. Vitamin D and pregnancy: skeletal effects, nonskeletal effects, and birth outcomes. Calcif Tissue Int. 2013;92(2):128–39.

    Article  PubMed  CAS  Google Scholar 

  4. Dawodu A, Saadi HF, Bekdache G, Javed Y, Altaye M, Hollis BW. Randomized Controlled Trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency. J Clin Endocrinol Metab. 2013;98(6):2337–46.

    Article  PubMed  CAS  Google Scholar 

  5. Tobias JH, Cooper C. PTH/PTHrP activity and the programming of skeletal development in utero. J Bone Miner Res. 2004;19(2):177–82.

    Article  PubMed  CAS  Google Scholar 

  6. Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet. 2006;367(9504):36–43 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  7. Lawlor DA, Wills AK, Fraser A, Sayers A, Fraser WD, Tobias JH. Association of maternal vitamin D status during pregnancy with bone-mineral content in offspring: a prospective cohort study. Lancet. 2013;381(9884):2176–83.

    Article  PubMed  CAS  Google Scholar 

  8. Harvey NC, Javaid K, Bishop N, Kennedy S, Papageorghiou AT, Fraser R, et al. MAVIDOS Maternal Vitamin D Osteoporosis Study: study protocol for a randomized controlled trial. The MAVIDOS Study Group. Trials. 2012;13:13 [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  9. Solomon A. Far from the tree. New York: Scribner; 2012.

    Google Scholar 

  10. Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, et al. Age at menarche and racial comparisons in US girls. Pediatrics. 2003;111(1):110–3 [Comparative Study Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.].

    Article  PubMed  Google Scholar 

  11. Epelboym Y, Gendron RN, Mayer J, Fusco J, Nasser P, Gross G, et al. The interindividual variation in femoral neck width is associated with the acquisition of predictable sets of morphological and tissue-quality traits and differential bone loss patterns. J Bone Miner Res. 2012;27(7):1501–10 [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.].

    Article  PubMed  Google Scholar 

  12. Schlecht SH, Jepsen KJ. Functional integration of skeletal traits: an intraskeletal assessment of bone size, mineralization, and volume covariance. Bone. 2013;56(1):127–38.

    Article  PubMed  Google Scholar 

  13. Misra M, Klibanski A. Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):376–82 [Research Support, N.I.H., Extramural Review].

    Article  PubMed  CAS  Google Scholar 

  14. Miller KK, Meenaghan E, Lawson EA, Misra M, Gleysteen S, Schoenfeld D, et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2011;96(7):2081–8 [Randomized Controlled Trial Research Support, N.I.H., Extramural].

    Article  PubMed  CAS  Google Scholar 

  15. Thein-Nissenbaum J. Long term consequences of the female athlete triad. Maturitas. 2013;75(2):107–12.

    Article  PubMed  Google Scholar 

  16. Walsh JS, Eastell R, Peel NF. Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008;93(4):1317–23 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  17. Buttazzoni C, Rosengren B, Tveit M, Lanidn L, Nilsson J, Karlsson M. Does a childhood fracture predict low bone mass in young adulthood? A 27-year prospective controlled study. J Bone Miner Res. 2013;28(2):351–9.

    Article  PubMed  Google Scholar 

  18. Pye SR, Tobias J, Silman AJ, Reeve J, O’Neill TW. Childhood fractures do not predict future fractures: results from the European Prospective Osteoporosis Study. J Bone Miner Res. 2009;24(7):1314–8 [Multicenter Study Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  19. Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79(6):333–40.

    Article  PubMed  CAS  Google Scholar 

  20. Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007;40(3):638–44 [Clinical Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  21. Meier RP, Ing Lorenzini K, Uebelhart B, Stern R, Peter RE, Rizzoli R. Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta–a case report. Acta Orthop. 2012;83(5):548–50 [Case Reports Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  22. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349(5):457–63 [Case Reports Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  23. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19(7):1191–3 [Case Reports Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  24. Teti A. Bone development: overview of bone cells and signaling. Curr Osteoporos Rep. 2011;9(4):264–73 [Review].

    Article  PubMed  Google Scholar 

  25. Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis GG, Papaioannou NA, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011;10(4):280–91 [Evaluation Studies Review].

    Google Scholar 

  26. Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004;19(10):1742–5 [Case Reports Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  27. McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ. Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med. 1994;35(8):1338–41 [Case Reports].

    PubMed  CAS  Google Scholar 

  28. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68–73 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  29. Rozental TD, Deschamps LN, Taylor A, Earp B, Zurakowski D, Day CS, et al. Premenopausal women with a distal radial fracture have deteriorated trabecular bone density and morphology compared with controls without a fracture. J Bone Joint Surg Am. 2013;95(7):633–42 [Comparative Study].

    Article  PubMed  Google Scholar 

  30. Chevalley T, Bonjour JP, van Rietbergen B, Ferrari S, Rizzoli R. Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius. Bone. 2013;55(2):377–83.

    Article  PubMed  CAS  Google Scholar 

  31. Nelson-Dooley C, Della-Fera MA, Hamrick M, Baile CA. Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes. Curr Med Chem. 2005;12(19):2215–25 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  CAS  Google Scholar 

  32. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12S–7S; discussion 7S–9S.

    Google Scholar 

  33. Cooper C, Melton 3rd LJ. Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992;3(6):224–9.

    Article  PubMed  CAS  Google Scholar 

  34. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–33 [Research Support, N.I.H., Extramural].

    Article  PubMed  CAS  Google Scholar 

  35. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–12 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  36. Khosla S, Melton 3rd LJ. Clinical practice. Osteopenia. N Engl J Med. 2007;356(22):2293–300 [Research Support, N.I.H., Extramural Review].

    Article  PubMed  CAS  Google Scholar 

  37. Izuora KE, Alazraki N, Byrd-Sellers J, Tangpricha V, Nanes MS. Fracture assessment tool risk scores in bone density reports do not change physician prescribing behavior for osteoporosis. Am J Med Sci. 2011;342(1):5–8.

    Article  PubMed  Google Scholar 

  38. Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, et al. Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol. 2008;35(2):319–26 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    PubMed  Google Scholar 

  39. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315–22 [Clinical Trial Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  40. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–41 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  41. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–52 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  42. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22 [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  43. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729–37. doi:10.1002/jbmr.1893.

    Article  PubMed  CAS  Google Scholar 

  44. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172(12):930–6.

    Article  PubMed  Google Scholar 

  45. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349(17):1676–9; discussion −9. [Letter].

    Article  PubMed  CAS  Google Scholar 

  46. Siris ES. Bisphosphonates and iritis. Lancet. 1993;341(8842):436–7 [Case Reports Letter].

    Article  PubMed  CAS  Google Scholar 

  47. Erichsen R, Christiansen CF, Froslev T, Jacobsen J, Sorensen HT. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Br J Cancer. 2011;105(7):881–3 [Comparative Study Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  48. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009;103(6):824–8.

    Article  PubMed  CAS  Google Scholar 

  49. Ho YF, Lin JT, Wu CY. Oral bisphosphonates and risk of esophageal cancer: a dose-intensity analysis in a nationwide population. Cancer Epidemiol Biomarkers Prev. 2012;21(6):993–5.

    Article  PubMed  CAS  Google Scholar 

  50. Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer–a pathway through the confusion. Nat Rev Rheumatol. 2011;7(6):369–72 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  51. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  52. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37 [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  53. Chesnut 3rd CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267–76 [Clinical Trial Comparative Study Multicenter Study Randomized Controlled Trial].

    Article  PubMed  CAS  Google Scholar 

  54. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821–9 [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  55. In brief: cancer risk with salmon calcitonin. Med Lett Drugs Ther. 2013;55(1414):29 [News]

    Google Scholar 

  56. Lobo R. Where are we 10 years after the women’s health initiative? J Clin Endocrinol Metab. 2013;98:1771–80.

    Article  PubMed  CAS  Google Scholar 

  57. Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein F, Heiman JR, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008;15(4 Pt 1):584–602 [Practice Guideline].

    PubMed  Google Scholar 

  58. Archer DF, Oger E. Estrogen and progestogen effect on venous thromboembolism in menopausal women. Climacteric. 2012;15(3):235–40 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  CAS  Google Scholar 

  59. Miller VM, Manson JE. Women’s health initiative hormone therapy trials: new insights on cardiovascular disease from additional years of follow up. Curr Cardiovasc Risk Rep. 2013;7(3):196–202.

    Article  PubMed  Google Scholar 

  60. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst. 2013;105(8):526–35 [Multicenter Study].

    Article  PubMed  CAS  Google Scholar 

  61. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65 [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  62. Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int. 2011;20(117):145–8 [Comparative Study]

    Google Scholar 

  63. Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, et al. Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone. 2013;55(2):305–8.

    Article  PubMed  CAS  Google Scholar 

  64. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27(12):2429–37.

    Article  PubMed  CAS  Google Scholar 

  65. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  66. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–39 [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  67. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002;13(3):257–64 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  PubMed  CAS  Google Scholar 

  68. Dawson-Hughes B. What is the optimal dietary intake of vitamin D for reducing fracture risk? Calcif Tissue Int. 2013;92(2):184–90 [Research Support, U.S. Gov’t, Non-P.H.S.].

    Article  PubMed  CAS  Google Scholar 

  69. Moyer VA. Vitamin D, and calcium supplementation to prevent fractures in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;158(9):691–6 [Research Support, U.S. Gov’t, P.H.S.].

    PubMed  Google Scholar 

  70. Reid IR, Bolland MJ. Does widespread calcium supplementation pose cardiovascular risk? Yes: the potential risk is a concern. Am Fam Physician. 2013;87(3):Online [Editorial]

    Google Scholar 

  71. Lutsey PL, Michos ED. Vitamin D, calcium, and atherosclerotic risk: evidence from serum levels and supplementation studies. Curr Atheroscler Rep. 2013;15(1):293 [Research Support, N.I.H., Extramural Review].

    Article  PubMed  Google Scholar 

  72. Haghighi A, Samimagham H, Gohardehi G. Calcium and vitamin d supplementation and risk of kidney stone formation in postmenopausal women. Iran J Kidney Dis. 2013;7(3):210–3.

    PubMed  Google Scholar 

  73. Kasturi KS, Chennareddygari S, Mummadi RR. Effect of bisphosphonates on bone mineral density in liver transplant patients: a meta-analysis and systematic review of randomized controlled trials. Transpl Int. 2010;23(2):200–7 [Meta-Analysis].

    Article  PubMed  CAS  Google Scholar 

  74. Conley E, Muth B, Samaniego M, Lotfi M, Voss B, Armbrust M, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation. 2008;86(2):231–7 [Research Support, N.I.H., Extramural].

    Article  PubMed  CAS  Google Scholar 

  75. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 2011;63(2):325–8.

    Article  PubMed  CAS  Google Scholar 

  76. Heaney RP. Nutrition and osteoporosis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 3rd ed. Philadelphia: Lippincott-Raven; 1996.

    Google Scholar 

  77. McCloskey EV, Johansson H, Oden A, Kanis JA. From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 2009;7:77–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA

    Margaret Seton MD

Authors
  1. Margaret Seton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret Seton MD .

Editor information

Editors and Affiliations

  1. Department of Rheumatology, Gretchen and Edward Fish Center for Women’s Health,, Brigham and Women’s Hospital, Chestnut Hill, Massachusetts, USA

    Elinor Mody

  2. Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Elizabeth Matzkin

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Seton, M. (2014). Women’s Bone Health: Breathing Life into the Skeleton. In: Mody, E., Matzkin, E. (eds) Musculoskeletal Health in Women. Springer, London. https://doi.org/10.1007/978-1-4471-4712-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4712-1_3

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4711-4

  • Online ISBN: 978-1-4471-4712-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation